Orchard Therapeutics appoints Board member and CSO Dr Bobby Gaspar as CEO

– UK, London / USA, MA –  Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that company founder and gene therapy pioneer Bobby Gaspar, M.D., Ph.D., has been named CEO, effective immediately.

Dr. Gaspar, previously president of research, CSO and a member of the board of directors, succeeds Mark Rothera, who has served as the CEO since 2017. As part of this transition process, Frank Thomas, COO and CFO, will take on the role of president.

“As a world-renowned scientist and physician, and accomplished strategic and organizational leader with more than 25 years of experience in medicine and biotechnology, Bobby Gaspar is uniquely qualified to lead Orchard into the future,” said Jim Geraghty, Chairman.

“In addition, Frank Thomas’ proven track record of success in leading operations, corporate finance and commercialization at a number of publicly-traded life sciences companies will continue to be invaluable in his expanded role. On behalf of the entire Board of Directors, I’d like to personally thank Mark for his many contributions to building Orchard into a leading gene therapy company over the last three years and wish him all the best in his future endeavours,” he added.

Mr. Thomas commented: “I’m excited to be part of this next phase of Orchard’s evolution as a gene therapy leader as we look to refine our strategic priorities, ensure financial strength through improved operating efficiencies and prepare for a new cycle of growth, which includes our anticipated upcoming launch of OTL-200 in Europe. I’m confident we will achieve long-term growth and value for our shareholders while turning groundbreaking innovation into potentially transformative therapies for patients suffering from devastating, often-fatal inherited diseases.”

Mr. Rothera commented: “It has been a great privilege to lead Orchard and this outstanding management team for the past three years. Orchard is poised to make a huge difference to the lives of patients worldwide living with devastating rare genetic conditions. Having worked closely with Bobby for the last several years, I know that he is tremendously talented, extremely passionate about the patient-centric mission, and fully prepared to lead Orchard as it enters its next phase as a company.”

About Dr Bobby Gaspar

One of the company’s principal scientific founders, Dr Gaspar has served on Orchard’s board of directors and has driven its research, development and regulatory strategy since its inception. Over the course of his long career, he has been a leading force in the development of hematopoietic stem cell gene therapy – bringing it from some of the first studies in patients to potential regulatory approvals. Dr. Gaspar’s unparalleled expertise, in addition to his deep relationships with key physicians and treatment centers around the world, will continue to be integral to efforts to identify and treat patients with metachromatic leukodystrophy and other diseases through targeted disease education, early diagnosis and comprehensive newborn screening.

Dr. Gaspar commented: “I am honored to become Orchard’s next CEO at a time of such opportunity for the company and for patients with severe genetic disorders. Through the consistent execution of our strategy, our talented team has advanced a leading portfolio of gene therapy candidates, expanding our R&D, manufacturing and commercial capabilities. We will now focus on driving continued innovation and growth, as well as strong commercial preparation and execution. I look forward to providing greater detail around our commercialization plan, pipeline prioritization and how we can realize the full potential of our HSC gene therapy platform, in the coming quarter.”

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to permanently correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders.

Orchard has its global headquarters in London and U.S. headquarters in Boston.

For more information: https://www.orchard-tx.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>